

Maine Coon



LABGENVET (2021)

Hypertrophic Cardiomyopathy

Maine Coon (117 tests)

N/N	76.0%
M/N	21.4%
M/M	2.6%

Pyruvate Kinase Deficiency

(39 tests)

N/N	92.3%
M/N	7.7%
M/M	0.0%

Polycystic Kidney Disease (PKD)

(5 tests)

N/N	60.0%
M/N	40.0%
M/M	0.0%

Anderson (2022)

Hypertrophic Cardiomyopathy

Maine Coon (1840 tests)

N/N	91.9%
M/N	7.7%
M/M	0.4%

Pyruvate Kinase Deficiency

(1824 tests)

N/N	85.1%
M/N	14.3%
M/M	0.6%

Polycystic Kidney Disease (PKD)

(1835 tests)

N/N	99.8%
M/N	0.2%
M/M	0.0%

Factor XII Deficiency (Variant 2)

(259 tests)

N/N	79.2%
M/N	19.3%
M/M	1.5%

Factor XII Deficiency (Variant 1)

(1836 tests)

N/N	88.8%
M/N	10.9%
M/M	0.3%

MDR1 Medication Sensitivity

(1840 tests)

N/N	94.5%
-----	-------

M/N	5.4%
M/M	0.1%

Mucopolysaccharidosis Type VI Modifier

(1840 tests)

N/N	99.8%
M/N	0.2%
M/M	0.0%

Progressive Retinal Atrophy (Abyssinian)

(PRA-rdAc) (1840 tests)

N/N	99.9%
M/N	0.1%
M/M	0.0%

Spinal Muscular Atrophy (Maine Coon)

(1840 tests)

N/N	99.4%
M/N	0.6%
M/M	0.0%

Cystinuria type B (Variant 3)

(1840 tests)

N/N	99.7%
M/N	0.3%
M/M	0.0%

Congenital Erythropoietic Porphyria (c.140C>T)

(1840 tests)

N/N	99.9%
M/N	0.1%
M/M	0.0%